AACE Annual Meeting 2026 Preview: 7 Trials to Know

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 kicks off in Las Vegas, Nevada, on Wednesday, April 22, 2026. As the global burden of obesity, diabetes, dyslipidemia, and other related conditions continues to rise, this year's conference is set to explore the latest evidence-based strategies, clinical innovations, and interdisciplinary approaches that position nutrition as both a therapeutic tool and a foundation for lifelong health.

The meeting is structured to provide relevant, practical, and immediate application of clinical education for endocrinologists, fellows, primary care physicians, physicians assistants, nurse practitioners, nurses, diabetes care and education specialists, clinical pharmacists, registered dietitians, and others in the endocrine care team. This year’s AACE meeting boasts more than 2200 attendees, 110 speakers, and 80 sessions across the 3-day conference.

The HCPLive editorial team will be on site at the conference, providing written coverage of practice-shifting data as well as interviews with key experts. You can keep up with our comprehensive conference coverage here. Check out what can be expected from this year’s meeting below:

Expert Interviews

Scott Isaacs, MD, who will discuss advances in prediabetes and diabetes prevention as well as multidisciplinary approaches to MASLD and MASH

Viral Shah, MD, who will discuss clinical outcomes associated with continuation versus discontinuation of insulin pump therapy in hospitalized adults with diabetes as well as GLP-1 use in type 1 diabetes and obesity

W Timothy Garvey, MD, who will discuss whether clinicians should continue to use BMI when talking about obesity

Richard Auchus, MD, PhD, who will discuss 2-year results from the CAHtalyst Adult study of crinecerfont in adults with classic congenital adrenal hyperplasia

Trials to Watch

1. Tirzepatide vs Semaglutide for Glycemic Control and Weight Loss: Updated Network Meta-Analysis of Phase 3 Trials Incorporating 2025 SURMOUNT-5 Data

Presentation Time: 10:50am on Wednesday, April 22

Presenter(s): Mohamed Ahmed, MD, and Sameer Bhimani, MD

2. Characterization of Proptosis Response Among Responders Treated with Veligrotug in the THRIVE Phase 3 Trial for Active Thyroid Eye Disease (TED)

Presentation Time: 3:10pm on Wednesday, April 22

Presenter(s): Jody Abrams, MD, Steven Leibowitz, MD, Raghu Mudumbai, MD, et al

3. Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Fasting Blood Glucose

Presentation Time: 11:10am on Thursday, April 23

Presenter(s): Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

4. Efficacy And Safety of Semaglutide Injection in Type 2 Diabetes Mellitus: A Phase 3 Study Subgroup Analysis Based on Post Prandial Blood Glucose

Presentation Time: 11:30am on Thursday, April 23

Presenter(s): Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

5. Correlation of Weight loss and 36-Item Short Form Survey Total score in weight management with Semaglutide injection: Post-hoc Analysis of Phase 3 Study

Presentation Time: 11:50am on Thursday, April 23

Presenter(s): Pravin Ghadge, MD, Ambika UnniKrishnan, MD, Ameya Joshi, MD, et al

6. Relacorilant Treatment Improves Glycemic Control Among Individuals With Endogenous Hypercortisolism and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study

Presentation Time: 8:20am on Friday, April 24

Presenter(s): Julie Silverstein, MD, Georgiana Dobri, MD, Atanaska Elenkova, MD, et al

7. Crinecerfont Improves Cardiometabolic Outcomes Associated With Chronic Supraphysiologic Glucocorticoid Exposure: 1-Year Results from CAHtalyst™ Adult

Presentation Time: 11am on Friday, April 24

Presenter(s): Oksana Hamidi, DO, MSCS, Irina Bancos, MD, Nicole Reisch, MD, et al.